Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GamCoviMab
- Development stage
- Phase 2
- Lead developer
- Gamaleya Center
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**GamCoviMab** is an investigational intravenous anti-SARS-CoV-2 antibody cocktail developed by the Gamaleya National Research Center for Epidemiology and Microbiology. It contains two humanized single-domain neutralizing antibody components, GamP2C5 and GamXRH19, directed against the receptor-binding domain of the SARS-CoV-2 spike protein. By binding the viral spike receptor-binding domain, the antibodies are intended to neutralize SARS-CoV-2 and prevent viral entry into host cells. The product has been studied for early etiotropic treatment of confirmed COVID-19 and has also been described by its developer as a candidate for prevention of coronavirus infection.
- Other names
- gamkovimabГамКовиМаб
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on GamCoviMab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GamCoviMab.